🚀

오늘의 열정을 계속 이어가세요!

체험은 만족하셨나요? 지식 자료를 소장하고 멋진 의료인으로 성장하세요!

구경하기
Other Antineoplastic Medications | 마이메르시 MyMerci
제안하기

뭔가 하고 싶은 말이 있는거야?

제안하기
닫기
컨텐츠 수정하기

컨텐츠 내용을 수정할 수 있습니다

수정하기
닫기

Other Antineoplastic Medications

NCLEX Review Guide: Other Antineoplastic Medications

Hormonal Antineoplastic Agents

Antiestrogens & SERMs

  • Tamoxifen (Nolvadex) blocks estrogen receptors in breast tissue, used for estrogen-receptor positive breast cancer treatment and prevention. Selective Estrogen Receptor Modulator (SERM) acts as estrogen antagonist in breast tissue but agonist in bone.
  • Raloxifene (Evista) prevents breast cancer in high-risk postmenopausal women while protecting bone density. Unlike tamoxifen, it doesn't increase endometrial cancer risk.

Clinical Scenario

A 55-year-old postmenopausal woman on tamoxifen reports irregular vaginal bleeding. This requires immediate gynecological evaluation as tamoxifen increases endometrial cancer risk.

Key Points

  • Monitor for thromboembolic events - increased DVT/PE risk
  • Tamoxifen increases endometrial cancer risk; raloxifene does not
  • Both medications can cause hot flashes and mood changes

Aromatase Inhibitors

  • Anastrozole (Arimidex) and Letrozole (Femara) block estrogen synthesis in postmenopausal women. These medications are more effective than tamoxifen for hormone-receptor positive breast cancer.
  • Used only in postmenopausal women because premenopausal ovaries can overcome aromatase inhibition. Aromatase enzyme converts androgens to estrogens in peripheral tissues.

Key Points

  • Bone density monitoring required - increased osteoporosis risk
  • Joint pain and stiffness common side effects
  • Lower thromboembolic risk compared to tamoxifen

Targeted Therapy Agents

Monoclonal Antibodies

  • Trastuzumab (Herceptin) targets HER2-positive breast cancer cells by binding to HER2 receptors. Cardiotoxicity monitoring essential with baseline and periodic echocardiograms or MUGA scans.
  • Rituximab (Rituxan) targets CD20 protein on B-lymphocytes, used for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Can cause severe infusion reactions during first administration.

Memory Aid

HEART for Trastuzumab monitoring:
Heart function assessment
Echocardiogram baseline
Arrhythmia monitoring
Regular cardiac evaluation
Terminate if EF drops significantly

Key Points

  • Premedication with antihistamines and corticosteroids for infusion reactions
  • Monitor for tumor lysis syndrome with rituximab
  • Trastuzumab contraindicated with significant cardiac dysfunction

Tyrosine Kinase Inhibitors

  • Imatinib (Gleevec) blocks BCR-ABL tyrosine kinase in chronic myeloid leukemia, revolutionizing CML treatment with oral administration. Tyrosine kinase enzymes promote cell growth and division in cancer cells.
  • Gefitinib (Iressa) targets EGFR mutations in non-small cell lung cancer, particularly effective in Asian populations and non-smokers with specific genetic mutations.

Key Points

  • Monitor CBC for myelosuppression, especially with imatinib
  • Liver function monitoring required - hepatotoxicity risk
  • Drug interactions common due to CYP450 metabolism

Commonly Confused Points

Medication Mechanism Primary Toxicity Patient Population
Tamoxifen Estrogen receptor blocker Endometrial cancer, DVT Pre/postmenopausal
Aromatase Inhibitors Block estrogen synthesis Osteoporosis, joint pain Postmenopausal only
Trastuzumab HER2 receptor blocker Cardiotoxicity HER2-positive tumors
Imatinib Tyrosine kinase inhibitor Myelosuppression CML patients

Quick Check: Common Pitfalls

  • ❌ Using aromatase inhibitors in premenopausal women
  • ❌ Forgetting cardiac monitoring with trastuzumab
  • ❌ Missing infusion reaction premedication
  • ❌ Ignoring drug interactions with oral targeted agents

Study Tips & Memory Aids

Hormonal Agent Memory Aid

ESTROGEN pathway blocking:
Estrogen receptor blockers (Tamoxifen)
Synthesis blockers (Aromatase inhibitors)
Targeted for hormone-positive cancers
Require hormone receptor testing
Osteoporosis risk with AIs
Gynecologic monitoring with tamoxifen
Endometrial cancer screening
Not effective in hormone-negative tumors

    Targeted Therapy Administration Steps

  1. Verify genetic/protein marker status (HER2, EGFR, etc.)
  2. Obtain baseline assessments (cardiac function, CBC, LFTs)
  3. Premedicate for infusion reactions if indicated
  4. Monitor vital signs during and after infusion
  5. Assess for immediate adverse reactions
  6. Schedule appropriate follow-up monitoring

Self-Assessment Checklist

  • ☐ Can differentiate between tamoxifen and aromatase inhibitor mechanisms
  • ☐ Know cardiac monitoring requirements for trastuzumab
  • ☐ Understand infusion reaction prevention strategies
  • ☐ Recognize appropriate patient populations for each drug class
  • ☐ Identify key toxicities and monitoring parameters

Remember: These targeted therapies represent precision medicine - matching the right drug to the right patient based on tumor characteristics. Your understanding of these mechanisms and monitoring requirements will help you provide safe, effective patient care. You've got this! 💪

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.